CLINICAL VIGNETTE

Prosthetic valve endocarditis and acute heart failure in a patient after transcatheter aortic valve implantation procedure

Tomasz Skowerski, Patryk Grzywocz, Mariusz Bałys, Mariusz Skowerski, Zbigniew Gasior

Department of Cardiology, Medical University of Silesia, Upper Silesian Medical Centre, Katowice, Poland

An 88-year-old Caucasian man with a history of severe aortic stenosis treated with transcatheter aortic valve implantation (TAVI) was referred to our hospital due to a suspicion of prosthetic valve endocarditis (PVE). Previously the patient had undergone coronary artery bypass graft surgery (in 1993). The TAVI (using a 27-mm LOTUS bioprosthesis) was performed two months prior to admission, via transfemoral approach, and a third-degree atrioventricular block occurred during the procedure; therefore, a dual-chamber pacemaker was implanted immediately in a hybrid suite. Cefazolin was administered (2 g i.v.) as an antibiotic prophylaxis. The patient had had a recurrent fever (38°C) and progressing fatigue for two weeks before hospital admission. The C-reactive protein (CRP) level was 85 mg/L, white blood cell count was 13,000/µL, and haemoglobin level was 8.8 g/dL. Transthoracic echocardiography performed on admission showed slightly reduced left ventricular ejection fraction (50%), no malfunction of the aortic prosthesis, and no signs of PVE. Empiric antibiotic therapy with vancomycin was introduced. Transoesophageal echocardiography (TEE) revealed vegetations on the bioprosthetic leaflets and a large abscess in perivalvular tissues (Fig. 1A, B) infiltrating the native aortic root, aortic-mitral curtain, and the tricuspid annulus. Additionally, a mobile vegetation on the tricuspid valve was present, but there were no vegetations on the pacemaker leads. The blood culture test detected the presence of methicillin-resistant Staphylococcus epidermidis (MRSE). Vancomycin was continued and tigecycline was added to the therapy. Despite intensive treatment, the patient's clinical condition worsened — he developed septic shock and acute heart failure (New York Heart Association [NYHA] class IV). On physical examination a new diastolic murmur was discovered (3/6 in Levine scale). Pressor amines were administered. TEE was immediately repeated, and a large perivalvular perforated false aneurysm penetrating through fistula to right ventricle (RV) with a significant left-right leak was detected (Fig. 1C-E). Because of high risk (62.8% by EuroSCORE), the patient was excluded from surgery by a cardiothoracic surgeon. Intensive antibiotic and heart-failure therapies were continued for six weeks. The patient's condition improved — there was a decrease in NYHA (IV → II/III), no fever, and reduced fatigue. The control blood culture test was negative, CRP level was 9 mg/L, in TEE the LOTUS prosthesis had no signs of dysfunction (Fig. 1F), mild rocking, or paravalvular leak, the perivalvular abscess was almost empty, and the aorta-RV shunt was still




Figure 1. Transoesophageal echocardiography; A, C. Short axis view, aortic valve — abscess (arrow); B, D. Long axis view, aortic valve — vegetation (arrow); E. Short axis view, aorto-right ventricular fistula; F. Long axis view; aortic valve — regression of vegetation

present but not haemodynamically significant. The patient was discharged from hospital in good condition after nine weeks of therapy. He was prescribed rifampicin (based on antibiogram; 2×300 mg, p.o.) until the follow-up visit, enoxaparin due to atrial fibrillation, and heart failure treatment according to European Society of Cardiology guidelines. Unfortunately, six weeks after discharge a severe gastrointestinal bleeding followed by acute renal injury occurred and the patient died. Patients undergoing a TAVI procedure are often frail, and have various other comorbidities and a high EuroSCORE risk of cardiothoracic surgery [1]. PVE in this group is a rare but severe complication, occurring in 1% to 3% of patients. The options in those cases are limited: either an extremely risky surgery (in our case almost 63% by EuroSCORE) or a conservative treatment with antibiotics, which has very limited efficacy. The mortality after conservative treatment is high — both in-hospital and one-year — ranging from 47% to 64% and 66% to 75%, respectively [2]. Therefore, the prevention of PVE is crucial to avoid severe adverse events.

References

- Tokarek T, Sobczyński R, Dziewierz A, et al. Clinical outcomes in patients after surgical and transcatheter aortic valve replacement. Pol Arch Med Wewn. 2015; 125(10): 755–764, indexed in Pubmed: 26397310.
- 2015; 125(10): 755–764, indexed in Pubmed: 26397310.
 Cahill TJ, Baddour LM, Habib G, et al. Challenges in Infective Endocarditis.
 J Am Coll Cardiol. 2017; 69(3): 325–344, doi: 10.1016/j.jacc.2016.10.066, indexed in Pubmed: 28104075.

Address for correspondence:

Tomasz Skowerski, MD, Department of Cardiology, Medical University of Silesia, Upper Silesian Medical Centre, ul. Ziołowa 47, 40–635 Katowice, Poland, e-mail: tskowerski@gmail.com

Conflict of interest: none declared

Kardiologia Polska Copyright © Polish Cardiac Society 2018